


CV Template of KATRD International Conference 2020

Name	J. Mark Fitzgerald	
Country	Canada	
Organization	University of British Columbia	
Current Position	Professor of Medicine	

Educational Background

2016	European Respiratory Society	Fellow
1996	College of Physicians and Surgeons of Ireland (Medicine)	FRCPI
1982-1986	Royal College of Physicians and Surgeons Canada (Medicine and Respiratory)	FRCPC
1978-1981	College of Physicians and Surgeons of Ireland (Medicine)	MRCPI
1972-1978	University College Dublin (Medicine)	MB, BCH, BAO

Professional Experiences

2006/07/01 - present	University of British Columbia	Head, UBC Respiratory Division
2002/07/01 - present	University of British Columbia	Professor
2001/11/01 - present	University of British Columbia	Associate Member, Health Care & Epidemiology
2001/09/01 - present	BC Centre for Disease Control Society	Consultant
1989/07/01 - present	Vancouver General Hospital	Consultant Respiratory Physician

Professional Organizations

2015/07/20 – present	Vancouver Coastal Health Research Institute	Director, Centre for Lung Health
2005/07/01 – 2015/06/30	University of British Columbia	Head, VGH Respiratory Division
2002/07/01 – present	UBC	Professor
2001/09/01 – 2008/08/01	Vancouver General Hospital	Director Clinical Epidemiology and Evaluation Centre
1999/05/01 - 2002/06/30	UBC	Associate Professor
1995/07/01 - 1998/07/31	UBC	Associate Professor
1989/07/01 - 2001/09/30	BC Centre for Disease Control Society	Director, TB Control for Aboriginals
1989/07/01 - 1995/06/30	UBC	Assistant Professor
1988/07/01 - 1989/06/30	McMaster University	Assistant Professor
1987/07/01 - 1988/06/30	McMaster University	Clinical Scholar
1984/07/01 - 1987/06/30	McMaster University	Pulmonary and Research Fellow
1984/01/01 - 1984/06/30	Sligo General Hospital	Locum Consultant Physician
1982/01/01 - 1983/12/31	Sligo General Hospital	Pediatric Resident
1982/01/01 - 1982/12/30	Queen Elizabeth II Hospital Lesotho	Consultant Physician
1981/01/01 - 1981/06/30	Mater Misericordiae Hospital, Dublin	Medical Resident
1979/07/01 - 1980/12/31	Sligo General Hospital	Medical Resident
1979/01/01 - 1979/06/30	Mater Misericordiae Hospital, Dublin	Medical Intern
1978/07/01 - 1978/12/31	Mater Misericordiae Hospital, Dublin	Surgical Intern

Main Scientific Publications

1. Bleeker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β_2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*. 2016 Sep 2. pii: S0140-6736(16)31324-1. doi: 10.1016/S0140-6736(16)31324-1. PMID: 27609408
 2. FitzGerald JM, Bleeker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2016 Sep 5. pii: S0140-6736(16)31322-8. doi: 10.1016/S0140-6736(16)31322-8. PMID: 27609406
 3. O'Byrne P. M. FitzGerald JM, Zhong, N et al. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials. *Trials* 2017 Jan 10;18(1):12. doi: 10.1186/s13063-016-1731-4.
 4. FitzGerald JM, Emery P. Modifying the trajectory of asthma-are there lessons from the use of biologics in rheumatology? *Lancet*. 2017 Mar 18;389(10074):1082-1084. doi: 10.1016/S0140-6736(17)30600-1. PMID:28322805
 5. Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemièrre C, Field SK, McIvor RA, Hernandez P, Mayers I, Mulpuru S, Alvarez GG, Pakhale S, Mallick R, Boulet LP; Canadian Respiratory Research Network. Re-evaluation of Diagnosis in Adults with Physician-Diagnosed Asthma. *JAMA*. 2017 Jan 17;317(3):269-279. doi: 10.1001/jama.2016.19627. PMID:28114551
 6. O'Byrne PM, FitzGerald JM, Zhong N, Bateman E, Barnes PJ, Keen C, Almqvist G, Pemberton K, Jorup C, Ivanov S, Reddel HK. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials. *Trials*. 2017 Jan 10;18(1):12. doi: 10.1186/s13063-016-1731-4. PMID:28069068
 7. FitzGerald JM, Tavakoli H, Lynd LD, Al Efraij K, Sadatsafavi M. The impact of inappropriate use of short acting beta agonists in asthma. *Respir Med*. 2017 Oct;131:135-140. doi: 10.1016/j.rmed.2017.08.014. Epub 2017 Aug 17. PMID: 28947020
 8. FitzGerald JM, Bleeker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. *Lancet Respir Med*. 2017 Sep 8. pii: S2213-2600(17)30344-2. doi: 10.1016/S2213-2600(17)30344-2. PMID: 28919200
 9. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. *N Engl J Med*. 2018 May 17;378(20):1865-1876
-

-
10. Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. *N Engl J Med*. 2018 May 17;378(20):1877-1887
 11. Chen W, FitzGerald JM, Lynd LD, Sin DD, Sadatsafavi M. Long-Term Trajectories of Mild Asthma in Adulthood and Risk Factors of Progression. *J Allergy Clin Immunol Pract*. 2018 May 7. pii: S2213-2198(18)30304-0
 12. FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. *Lancet Respir Med*. 2018 Jan;6(1):51-64.
 13. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *N Engl J Med*. 2018 Jun 28;378(26):2486-2496.
 14. Khakban A, FitzGerald JM, Tavakoli H, Lynd L, Ehteshami-Afshar S, Sadatsafavi M. Extent, trends, and determinants of controller/reliever balance in mild asthma: a 14 year population based. *Respir Res*. 2019 Feb 28;20(1):44. doi: 10.1186/s12931-019-1007-0
 15. Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, Buhl R, Cruz AA, Fleming L, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Pedersen SE, Sheikh A, Yorgancioglu A, Boulet LP. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. *Eur Respir J*. 2019 Jun 27;53(6). pii: 1901046. doi: 10.1183/13993003.01046-2019.
 16. YAGHOUBI M, Adibi A, Zafari Z, FitzGerald JM, et al Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States. *J Allergy Clin Immunol*. 2019 Dec 11. pii: S0091-6749(19)31634.
-